Gefitinib-d8

• UNSPSC Description:

  Gefitinib-d8 is a deuterium labeled Gefitinib. Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells[1][2].

• Target Antigen:

  Autophagy; EGFR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  98.42

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C1([2H])OC([2H])([2H])C([2H])([2H])N(CCCOC2=CC3=C(NC4=CC=C(F)C(Cl)=C4)N=CN=C3C=C2OC)C1([2H])[2H]

• Molecular Weight:

  454.95

• References & Citations:

  [1]Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23.|[2]Moasser MM, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61(19):7184-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  857091-32-8